ArticleOpen life sciences2025

Efficacy and safety of anti-PD-1/PD-L1 antibodies in patients with relapsed refractory diffuse large B-cell lymphoma: A meta-analysis.

Jiawen Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.